Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Home » Search
Search Results
4,410 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Company news
Two Purdue University professors and a physician at the Indiana University School of Medicine have created a company to develop nanotechnology devices for medical diagnostic and therapeutic applications. NanoSense Inc., based in West Lafayette, will design tiny chips that can sense biological processes or the dosing of a medicine from inside a patient’s body. The company is led by IU’s Dr. Arthur Ko, a radiation oncologist; Purdue’s Babak Ziaie, a professor of electrical and computer engineering; and Teimour Maleki, a research professor at Purdue's Birck Nanotechnology Center.
With a $167,000 grant from the Anthem Blue Cross and Blue Shield Foundation, IUPUI will launch the Indiana Schweitzer Fellows Program on Friday. It is the 13th U.S. program site for the Albert Schweitzer Fellowship program, which pays stipends to graduate students who work to address social and health disparities. The Indiana program will be run by Dr. Douglas B. McKeag, former chairman of family medicine at the IU School of Medicine. The grant will be used to implement the 5-2-1-0 Healthy Kids Countdown, a childhood obesity-prevention program, by Schweitzer Fellows throughout the state. The program will select 15 fellows and pay each of them an annual stipend of $3,000. Online applications are due March 1.
Endocyte Inc. priced shares for its initial public offering last week, moving one step closer toward raising more than $80 million to fund its cancer-drug development. The West Lafayette-based drug-development firm intends to sell 6.15 million shares for $13 to $15 apiece. That range would fetch $80 million to $92 million. Those figures include 802,500 shares that will be sold only if demand outstrips the initial allotment of shares of 5.35 million. If Endocyte sells only the smaller amount of shares, it would raise between $70 million and $80 million. In either case, more than $10 million of the funds would cover Endocyte’s costs in staging the IPO. Endocyte first indicated in August it would take itself public by selling shares worth $86.3 million, but not until Jan. 12 did it disclose the price range and number of shares to be sold. The company is developing six cancer drugs, most of which target cancer cells by binding to their receptors for the compound folate. Such receptors are “over-expressed” in cancer cells, compared with healthy cells, so Endocyte’s drugs have the potential to be more potent killing the cancers while attacking fewer healthy cells than existing chemotherapy agents. Endocyte’s leading drug, called EC145, is being tested to treat ovarian cancer that is resistant to platinum-based drugs, as well as to treat non-small-cell lung cancer.
Some health advocacy groups that say they are speaking for patients’ interests before legislatures, regulatory agencies or public forums fail to disclose their funding from Eli Lilly and Co. and other drugmakers, according to The New York Times. Citing a new study from Columbia University, the Times reported that Lilly paid $3.2 million to 161 health advocacy groups in the first half of 2007. But only one in four of the groups acknowledged Lilly’s support anywhere on their public websites, the study said. Only one in 10 disclosed Lilly as the sponsor of a specific grant, and none of them disclosed the exact amount. Lilly’s reports were studied because it was the first company to disclose such payments.
Down on luck, Lilly finds comfort in pets
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
Lilly imaging drug isn’t ready for approval, FDA says
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer’s disease isn’t ready for approval, according to U.S. regulators.
Council committee to consider North of South bonds
Approval would let city issue $98 million in bonds to finance its portion of the $155 million North of South mixed-use project set to be built on 14 acres north of South Street between Delaware Street and Virginia Avenue.
WellPoint headquarters snags $42M
Massachusetts-based Franklin Street Properties acquired the Monument Circle headquarters of insurance giant WellPoint Inc. late in 2010 for $42 million—a rich $196 per square foot—from an affiliate of locally based HDG Mansur.
Parking key issue in Rolls-Royce’s possible downtown move
Rolls-Royce Corp.’s decision whether to move about 2,500 office employees to a former Eli Lilly and Co. downtown campus could hinge on three critical factors—parking, incentives and lease terms for the space.
JA inducting four into Business Hall of Fame
Ceremony at Indiana Roof Ballroom on Feb. 17 will honor Michael G. Browning, David R. Frick, Stephen Russell and the late Eli Lilly.
Panel says Lilly’s Solpura isn’t ready for approval
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
Deal could give Lilly full diabetes deck
Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
Company news
Indiana University researchers won a $7 million, four-year grant from the National Institutes of Health’s Human Microbiome Project. Barbara Van Der Pol, an epidemiologist at the IU School of Medicine, and David Nelson, a molecular biologist at IU’s Bloomington campus, have been named co-investigators on IU's portion of the project, which has already been operating under the leadership of Dr. J. Dennis Fortenberry, professor of pediatrics at the IU School of Medicine. The researchers are studying at a microbial level sexually transmitted diseases in Hoosier men, which often lead to pain during urination and sex.
The School of Science at IUPUI won a $943,000 grant from the National Science Foundation to help minority students pursue careers in life sciences research. The money will fund the IUPUI Undergraduate Research Mentoring in the Biological Sciences Program, beginning this spring. Two-year fellowships will pay stipends to selected science students to conduct intensive research on “biosignaling,” the ability of cells to respond to their environments. The students also will attend seminars and presentations designed to help them toward a career in bioresearch. Lastly, the students will be paired with minority mentors who already hold graduate degrees.
Warsaw-based Zimmer Holdings Inc. Chief Executive David Dvorak said that demand for hip- and knee-replacement procedures will recover in the second half of 2011, when consumers have jobs and insurance again. "There will continue to be an impact until unemployment rates are reduced and [insurance] enrollment rates go back up," Dvorak told investors in a presentation at a conference hosted by J.P. Morgan in San Francisco, according to Reuters. "We're going in the right direction, but it's a slow recovery," he said. Sales of orthopedic implants, which Zmmer manufactures, have been especially hard-hit during the recent recession, as patients out of work or short of cash put off elective surgeries.
WellPoint Inc. expects its profit this year to exceed $6.60 a share, the company announced Monday at the J.P. Morgan health care conference in San Francisco. Such a performance would slightly beat the expectations of Wall Street analysts, who currently predict 2011 profit of $6.57 per share for the Indianapolis-based health insurer. Analysts expect the same amount of profit when WellPoint reports its 2010 results on Jan. 26, according to a survey by Thomson Reuters. WellPoint provides health benefits to 33.5 million Americans, more than any other company. But the job losses of the past two years have kept its profits from growing.
An experimental drug being developed by Eli Lilly and Co. doesn’t appear to help with digestion as much as existing drugs, according to a staff report released Monday by the U.S. Food and Drug Administration. According to Bloomberg News, Lilly’s drug liprotamase, also known as Solpura, is designed to help patients suffering from poor digestion due to cystic fibrosis, chronic pancreatitis or other conditions. Outside advisers to the FDA are scheduled to meet today in Maryland to review whether the drug should be approved for those patients. The panel of advisers will issue a non-binding recommendation to the FDA, which will make the final decision. Indianapolis-based Lilly got rights to Solpura in July when it purchased Massachusetts-based Alnara Pharmaceuticals Inc. for up to $380 million.
UPDATE: Analysts praise Lilly diabetes deal with Boehringer
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
Lilly agrees to pay up to $1.2B for diabetes drugs
A complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
Lilly partner moves up timetable for diabetes drug
Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
Aprimo sale may usher in ‘new wave’ of tech deals
Observers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not only among IT firms, but also among biotech companies here.
Lilly bumped up federal lobbying in third quarter
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
Company news
Two St. Vincent Health hospitals—Saint John’s Health System and St. Vincent Jennings Hospital—have started using the DOCS4DOCS service provided by the Indiana Health Information Exchange. DOCS4DOCS centralizes in electronic format all the lab results, radiology reports, transcriptions, pathology and hospital admissions reports, discharge and transfer reports from all participating Indiana hospitals, physician practices, labs and radiology centers. The service, which swaps more than 6 million messages each month, is paid for by hospitals and laboratories but provided free of charge to physicians. The exchange, based in Indianapolis, now has more than 80 hospitals and 19,000 physicians participating in its medical-record-sharing services.
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by former Eli Lilly and Co. executives, has been acquired by Swiss life sciences giant Roche. Some details of the transaction will be disclosed in February. Roche’s holdings include Roche Diagnostics, which employs more than 3,000 in Indianapolis at its North American headquarters. Marcadia has about a dozen employees at its 11711 N. Meridian St. headquarters, who have so far been sustained by the millions of dollars Marcadia has raised in venture capital and its partnerships with large drug companies.. Marcadia has been focusing on drugs to treat metabolic diseases such as diabetes and obesity. It previously partnered with drug giant New Jersey-based Merck & Co. Inc. and with Indianapolis-based Lilly. Last June, Marcadia and Lilly struck a deal to develop short-acting glucagon drugs to treat severe hypoglycemia. Roche’s big hope for a new diabetes drug, taspoglutide, had its clinical trials suspended in September due to severe digestive-tract side effects.
Lilly, other big drugmakers shut out by FDA in 2010
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
WINSTON: Focus on kitchen and boardroom tables
Many voters I talked with wanted to send a wakeup call to politicians of both parties that they should heed the words of Jim Carville to then-candidate Bill Clinton in 1992: “It’s the economy, stupid.”